<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; two</title>
	<atom:link href="http://www.tapanray.in/tag/two/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Sales Post Covid-19 Lockdown</title>
		<link>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-post-covid-19-lockdown</link>
		<comments>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/#comments</comments>
		<pubDate>Mon, 04 May 2020 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[customer-centricity]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[habit]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[oldest]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[post Covid-19]]></category>
		<category><![CDATA[preferences]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10054</guid>
		<description><![CDATA[Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer&#8217;s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global &#8230; <a href="http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why D&amp;I Is A Powerful Growth Driver For Pharma Industry</title>
		<link>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-di-is-a-powerful-growth-driver-for-pharma-industry</link>
		<comments>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/#comments</comments>
		<pubDate>Mon, 10 Jun 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[empathetic]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[facets]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9578</guid>
		<description><![CDATA[‘Diverse India’ now needs an ‘inclusive society’, vowed the Prime Minister of India, after his massive electoral win on May 23, 2019. Many may consider a part of it as rhetoric, notwithstanding, as and when the government policy of Diversity and Inclusion &#8230; <a href="http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does India Believe in Two Different Drug Quality standards?</title>
		<link>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-believe-in-two-different-drug-quality-standards</link>
		<comments>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/#comments</comments>
		<pubDate>Wed, 28 May 2014 07:33:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bossidy]]></category>
		<category><![CDATA[Charan]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Larry]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ram]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5458</guid>
		<description><![CDATA[“Maintain and sharpen your intellectual honesty so that you’re always realistic. See things as they are, not way you want them to be.” The above profound statement is what the Management Guru Ram Charan made in his book titled, ‘Execution: &#8230; <a href="http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Loss of Ranbaxy, Gain of Big Pharma…And Two Intriguing Coincidences</title>
		<link>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences</link>
		<comments>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/#comments</comments>
		<pubDate>Mon, 17 Mar 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[coincidences]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[double]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hypothesis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Machiavellian]]></category>
		<category><![CDATA[murkier]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whammy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5096</guid>
		<description><![CDATA[In March 2014, the largest pharma player of India by market capitalization, Sun Pharma, became the latest of the large Indian pharma exporters facing the US-FDA ‘Import Ban’ for drugs manufactured at its Gujarat-based plant. This news came as a &#8230; <a href="http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Two Paintings on the Same Canvas: &#8216;Truth About Drug Companies&#8217; and &#8216;Protecting Access to Medicines&#8217;</title>
		<link>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines</link>
		<comments>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/#comments</comments>
		<pubDate>Mon, 13 May 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[About It.]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Angell]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[canvas]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Deceive]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editor]]></category>
		<category><![CDATA[England]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[her]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[leading]]></category>
		<category><![CDATA[M.D.faculty]]></category>
		<category><![CDATA[Marcia]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NEJM]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[paintings]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[protecting]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[same]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[TheTruth]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[titled]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[What to]]></category>
		<category><![CDATA[world’s]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2280</guid>
		<description><![CDATA[As the saying goes, &#8220;Great people think alike&#8221;, many thought leaders of very high credibility across the globe, seem to think almost in similar lines when it comes to improving access to medicines for a large section of the global &#8230; <a href="http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Takes ‘Two to Tango’: Encashing Opportunities with Biologic drugs in India</title>
		<link>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india</link>
		<comments>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 11 Feb 2013 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Avesthagen]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[capital]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[large]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[Orchid]]></category>
		<category><![CDATA[patent-cliff]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[Shanta]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[venture]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1408</guid>
		<description><![CDATA[Despite current ‘Patent Cliff’ ongoing research on biologics is now at the forefront of the Global Pharmaceutical Industry.  The bottom-line impact of a successful new biologic molecule to treat intractable ailments like, cancer, blood disorders, Parkinson&#8217;s, Myasthenia Gravis, Multiple Sclerosis, &#8230; <a href="http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The top two reasons for not seeking medical treatment, across the population, are not poor ‘Access to Healthcare’ in India</title>
		<link>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india</link>
		<comments>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 07 Feb 2011 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Across]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[seeking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=305</guid>
		<description><![CDATA[“About 1.8 million children under age of 5 die in India every year; 68,000 mothers die due to maternal causes, and 52 million children in the country are stunted”. “With 70% people living in more than 600,000 villages across rural &#8230; <a href="http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
